

# Klinikum Stuttgart – Medizin fürs Leben

## Institutional variables in the European and American Osteosarcoma Study EURAMOS-1: **Pediatric and adolescent vs. young adult osteosarcoma patients**

**Stefan Bielack<sup>1,2</sup>, Jane Hook<sup>3</sup>, Gordana Jovic<sup>3</sup>, Neyssa Marina<sup>4</sup>; Sigbjørn Smeland<sup>5</sup>,  
Matthew R Sydes<sup>3</sup>, Jeremy Whelan<sup>6</sup>, Mark Bernstein<sup>7</sup>**

Klinikum Stuttgart - Olgahospital<sup>1</sup> and University Hospital Muenster<sup>2</sup>, Germany; MRC Clinical Trials Unit<sup>3</sup> & UCL Hospitals NHS Trust<sup>6</sup>, London, UK; Stanford University Medical Center, USA<sup>4</sup>; Norwegian Radium Hospital, Oslo, Norway<sup>5</sup>; IWK Health Centre, Dalhousie University, Halifax, Canada<sup>7</sup>




Supported by the European Science Foundation (ESF) under the EUROCORES Program European Clinical Trials (ECT), through contract No. ERASCT-2003-980409 of the European Commission, DG



# Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project

C.A. Stiller<sup>a,\*</sup>, S.S. Bielack<sup>b,c</sup>, G. Jundt<sup>d</sup>, E. Steliarova-Foucher<sup>e</sup>

EUROPEAN JOURNAL OF CANCER 42 (2006) 2124-2135













**EURAMOS-1**  
ISRCTN67613327  
EudraCT no. 2004-000242-20

A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy

Clinical trial protocol  
Version: 2.1  
Date: 21<sup>st</sup> April 2009

EURAMOS-1 Protocol, Version 2.1, 21 April 2009



### 3.1. Primary objectives

- In a randomized trial, to examine whether the addition of ifosfamide and etoposide (IE) to post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a poor histological response to 10 weeks of pre-operative chemotherapy.
- In a randomized trial, to examine whether the addition of pegylated interferon  $\alpha$ -2b (ifn) as maintenance therapy after post-operative chemotherapy with cisplatin, doxorubicin and methotrexate improves event-free survival for patients with resectable osteosarcoma and a good histological response to 10 weeks of pre-operative chemotherapy.



# EURAMOS


## main eligibility criteria

- **osteosarcoma** (high-grade, resectable)
- **age 0-40**
- **no previous chemo**



# EURAMOS Recruitment 04/05 – 06/11



**2,260 patients**  
 from **326 institutions**  
 in **17 countries**



Group	Freq.	Percent	Cum.
COG	1,164	51.50	51.50
COSS	520	23.01	74.51
EOI	457	20.22	94.73
SSG	119	5.27	100.00
<b>Total</b>	<b>2,260</b>	<b>100.00</b>	

Thanks to EURAMOS-CDC,  
 MRC London






- North America & Australasia
- Europe



# EURAMOS1

Final recruitment figures for Europe ( $\Sigma = 1,108$ )



# EURAMOS1

## Top 10 Recruiters




UK London: UCH	90	
Netherlands Leiden UMC	51	
Germany Münster: Univers. Kinderklinik	35	
Norway Oslo	30	
USA Children's Hospital of Philadelphia	26	
USA Children's Hospital and Regional Me	24	
Germany München: Kinderklinik & Polikli	23	
USA Doernbecher Childrens Hospital - OH	23	
USA University of Minnesota Cancer Cent	23	
Germany Hamburg: Univers. Paediat. Onco	22	
Germany Stuttgart: Olgahospital	22	

Sum 346/2,260 = 15.3% of total recruitment









## Osteosarcoma Incidence and Survival Rates From 1973 to 2004


Cancer 2009;115:1531-43.

Data From the Surveillance, Epidemiology, and End Results Program

Lisa Mirabello, PhD<sup>1</sup>, Rebecca J. Troisi, ScD<sup>2,3</sup>, and Sharon A. Savage, MD<sup>1</sup>








	<u>0-18 yr</u>	<u>19-40yr</u>	<u>p</u>
<b>n</b>	<b>1930</b>	<b>330</b>	
<b>male</b>	<b>57%</b>	<b>71%</b>	<b>&lt;.01</b>
<b>axial</b>	<b>4%</b>	<b>12%</b>	<b>&lt;.01</b>
<b>mets*</b>	<b>23%</b>	<b>24%</b>	<b>n.s.</b>




\* = definitive & possible mets








	<u>0-18 yr</u>	<u>19-40yr</u>	<u>p</u>
<b>n</b>	<b>1930</b>	<b>330</b>	
<b>male</b>	<b>57%</b>	<b>71%</b>	<b>&lt;.01</b>
<b>axial</b>	<b>4%</b>	<b>12%</b>	<b>&lt;.01</b>
<b>mets*</b>	<b>23%</b>	<b>24%</b>	<b>n.s.</b>
<b>randomized</b>	<b>59%</b>	<b>54%</b>	<b>n.s.</b>








**41%**



	<u>centers</u>	<u>pts</u>	<u>pts/center</u>
<b>only old</b>	23	<b>41</b>	<b>1.8</b>
<b>both</b>	110	<b>1191</b>	<b>10.8</b>
<b>only young</b>	193	<b>1028</b>	<b>5.3</b>




	<u>centers</u>	<u>pts</u>	<u>pts/center</u>
<b>only old</b>	23	<b>41</b>	<b>1.8</b>
<b>both</b>	110	<b>1191</b>	<b>10.8</b>
<b>only young</b>	193	<b>1028</b>	<b>5.3</b>






	<u>centers</u>	<u>pts</u>	<u>pts/center</u>
<b>only old</b>	23	<b>41</b>	<b>1.8</b>
<b>both</b>	110	1191 <b>289</b> 902	10.8 <b>2.6</b> 8.2
<b>only young</b>	193	<b>1028</b>	<b>5.3</b>



	<u>centers</u>	<u>pts</u>	<u>pts/center</u>
<b>old</b>	133	<b>330</b>	<b>2.5</b>
<b>young</b>	303	<b>1930</b>	<b>6.4</b>





# Conclusions

- **low degree of centralization**  
especially for older patients (young adults)
- most patients >18yr registered by institutions  
also caring for children/adolescents
- efforts targeting “adult” oncology seem to be warranted





# Conclusions

- efforts targeting “adult” oncology



The EURAMOS investigators thank

**ESF**

and its Member Organisations

for their support



Supported by the European Science Foundation (ESF) under the EUROCORES Program European Clinical Trials (ECT), through contract No. ERASCT-2003-980409 of the European Commission, DG



# Klinikum Stuttgart – Medizin fürs Leben

Danke für Ihre Aufmerksamkeit!

